Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, will be announcing its interim results for the six months ended 30 December 2006 on Tuesday 6 February 2007.
An analyst presentation will take place on the day at 10:00am at Buchanan Communications, 45 Moorfields, London EC2Y 9AE.
In addition, on the same day, Sareum will be providing a research and development update at 10.30am also at the offices of Buchanan Communications.
The R&D update will include the following presentations:
What big pharma needs from biotech
Professor David Tapolczay, Vice President, Technology Development, GlaxoSmithKline
Levering biotech collaborations to attract big pharma licencing deals
Dr Stephen Mayhew, Business Manager, Cancer Research Technology
Sareum's in-house pipeline and licencing strategy
Dr John Reader, Founder and VP Chemistry, Sareum
Presentations will be available for 1 month from 9.30am on 6 February 2007 from Request Presentations.
For further information:
Sareum Holdings 01223 497700
Tim Mitchell, Chief Executive Officer
Buchanan Communications 020 7466 5000
Tim Anderson, Mary-Jane Johnson
Notes for editors:
About Sareum Holdings plc
Sareum Holdings plc is a structure-based drug discovery business headquartered in Cambridge, UK. The Company was formed in August 2003 to discover new drugs for the treatment of cancer. Sareum's unique approach aims to halve the time it takes to discover new drug candidates.
A structure-based approach to drug discovery relies on knowledge of the three-dimensional structure of the proteins that cause disease. Once the structure is known, potential drugs are designed to 'lock-in' to the protein with the aim of reversing or arresting a disease's progression. Knowledge of the structure of the potential drugs and how they 'lock-in' to their target protein assists greatly in the development of high-quality drug candidates. Determining structure is a complex task and requires leading-edge equipment and experienced staff. Sareum's approach to structure determination utilises its proprietary protein expression platform in order to produce multiple recombinant proteins that accelerate structure determination using x-ray crystallography.
Once the structure is determined, the Company's innovative fragment screening platform is used to identify novel chemical templates designed to interact with the target protein. Sareum then uses its high-throughput medicinal chemistry platform to rapidly optimise these molecules and develop the most promising into potential drug candidates.
Sareum aims to successfully deliver drug candidates for licensing to larger pharmaceutical companies at the pre-clinical or early clinical trials stage. This is funded by provision of its specialist drug discovery capabilities to partners in the pharmaceutical and biotechnology industries.
Sareum joined the AIM market of the London Stock Exchange in October 2004 and trades under the symbol SAR. For further information, please visit www.sareum.co.uk